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Abbreviations used in this article:
BD, Behçet’s disease; BDa, BD patients with active oral ulcers; BDq, BD quiet patients without 
oral ulcers; RASa, recurrent aphthous stomatitis patients with active oral ulcers; RASq, recurrent 
aphthous stomatitis quiet patients without oral ulcers; NE, neutrophil elastase; SLPI, secretory 
leukocyte protease inhibitor; α1AT, alpha1-antitrypsin; HC, healthy control; OBS, oral buccal 
swabs (U, ulcerated site; NU, non-ulcerated site); qPCR, quantitative PCR; ECM, extracellular 
matrix; CatG, Cathepsin G; AZA, azathioprine; COLC, colchicine. WBC, white blood cell.
Summary
Behçet’s disease (BD) is a vasculitis of unknown aetiology typified by chronic recurrent oral 
ulcers and systemic inflammatory manifestations. Neutrophils, and specifically their protease 
neutrophil elastase (NE), have been implicated in its pathology. Although NE is an effective 
antimicrobial, excessive NE can damage host tissue. Recurrent oral ulceration is a primary BD 
symptom, therefore we hypothesized that excessive neutrophil infiltration evidenced by increased 
NE and a reduction in specific endogenous inhibitors, secretory leukocyte protease inhibitor 
(SLPI) and alpha1-antitrypsin (α1AT), contributes to BD mucosal instability. NE, SLPI, and α1AT 
were quantified in saliva from BD patients with active oral ulcers (BDa) and quiet without ulcers 
(BDq), recurrent aphthous stomatitis (RASa; RASq), and healthy controls (HC). Although BDq 
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ng/ml) and HC (999 ng/ml), SLPI was significantly reduced in BDq (p<0.01). Despite decreased 
SLPI protein, mRNA expression was significantly increased in BDq buccal epithelial swabs 
compared to RASq and HC (p<0.05, p<0.001). NE remained enzymatically active although α1AT 
levels were at least eight times higher than SLPI in all groups suggesting α1AT does not have a 
primary role in counteracting NE in saliva. Furthermore, NE levels in BDa patients medicated 
with both azathioprine (AZA) and colchicine (COLC) were significantly lower than those on 
COLC (p=0.0008) or neither (p=0.02) indicating combining AZA+COLC may help regulate 
excessive NE during ulceration. This study showed that enzymatically active NE coupled with 
reduced SLPI in BD saliva may contribute to recurrent oral ulcerations. 
INTRODUCTION
Behçet’s disease (BD) is a chronic, multi-systemic disorder with evidence of both auto-
inflammatory and autoimmune characteristics typified by recurrent oral and genital 
mucocutaneous lesions (1, 2). Individuals may also experience arthritis, eye lesions, 
gastrointestinal issues, vascular inflammation, and/or neurological disorders. Although the 
mechanism of pathogenesis is unknown, there is some evidence of autoimmunity by way of anti-
endothelial cell antibodies as well as immune dysfunction with a genetic predisposition to the 
human leukocyte antigen complex, HLA-B51 (3-5) Oral ulceration occurs in all BD patients 
typically preceding systemic symptoms suggesting these ulcers are a key event in this disease (6). 
Morphologically, BD ulcers are similar to recurrent aphthous stomatitis (RAS) with a few 
differentiating characteristics (7). In BD, a large swollen peri-ulcer with erythema is visible. 
Majors ulcers tend to be destructive with scars distorting the oral mucosa (8). In RAS, peri-ulcer 
erythema is reduced and quickly diminishes as the ulcer heals from the base. During quiet 
episodes, BD patients frequently still have erythematous mucosal areas. Histologically, BD and 
RAS ulcers share similar features (9). Biopsies show infiltration of neutrophils, macrophages, T 
cells, and proinflammatory cytokines (1, 10). However, interleukin (IL)-4 has only been detected 
in BD ulcers (11). The dichotomy of IL-4 is that it has been shown to down-regulate neutrophil 
migration (12), but can also delay neutrophil apoptosis and induce IL-8, a potent neutrophil 
chemoattractant (13). There is a lack of research regarding the possible mechanisms that are 
involved in the induction of BD oral manifestations despite the fact that the initial onset of oral 
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Neutrophil chemotaxis and infiltration is evident in BD oral, ocular and cutaneous lesions and has 
been implicated in the disease’s progression and pathology (14-16). Gene HLA-B51, having the 
strongest association with BD (5), was also found to be associated with neutrophil hyperactivity 
(17). Treatment is aimed at preventing systemic reactivation. Immunomodulatory medication, 
such as colchicine, is used in patients with recurrent mucocutaneous BD to reduce neutrophil 
chemotactic activity (18). 
Neutrophil elastase (NE) is a serine protease produced mainly by promyelocytes (19). NE is 
contained in azurophilic granules alongside Cathepsin G (CatG) and Proteinase-3 in a ready-to-use 
state. The controlled mechanism of NE delivery consists of either the release of granules into a 
phagolysosome where microbes are degraded, or exocytosis of the azurophil into extracellular 
spaces (20). Uncontrolled release of NE can also be due to necrosis and/or NETosis (21, 22). 
Neutrophil degranulation can be triggered by various inflammatory factors or direct contact with 
the extracellular matrix (ECM) (23) and increased neutrophil recruitment can extend the duration 
of inflammation (24). High extracellular NE levels in chronically inflamed tissue of individuals 
with chronic obstructive pulmonary disease (COPD) (25) and inflammatory bowel disease has 
been implicated as a cause of tissue damage (24). Being kinetically faster than CatG and 
Proteinase-3 (26), NE is capable of quickly degrading ECM components such as elastin, collagen, 
and fibronectin (24). Therefore, NE regulation is vital.
Secretory leukocyte protease inhibitor (SLPI) has been reported as one of the primary regulatory 
inhibitors of NE in COPD patients’ sputum (27). SLPI is a stable innate inhibitory protein which 
has broad spectrum anti-microbial activity and protects mucosal epithelial surfaces from 
proteolytic enzymes such as NE, CatG, and trypsin (28). SLPI is produced in many cell types 
including saliva gland acinar cells and mucosal epithelial cells (29) and has been detected in 
various secretions including bronchial fluid (30) and saliva (31). 
Alpha1-antitrypsin (α1AT), a systemically circulating serine protease produced mainly in the liver, 
is a well-known inhibitor of NE in the lung. It has been measured in saliva (32) and gingival 
crevicular fluid in periodontal lesions (33). Notably, both SLPI and α1AT have also been 
identified in neutrophil cytoplasm separated from the enclosed NE granule suggesting neutrophils 
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Neutrophil infiltration is evident in BD oral ulcers, and uniquely, IL-4 which could delay 
neutrophil apoptosis. Degranulation is triggered by various inflammatory factors  such as TNF-α, 
IL-8, C5a and LPS (35) releasing excessive NE into the oral environment which can quickly 
degrade epithelial tissue (36). The aim of this study was to clarify the role of NE and its 
endogenous inhibitors in the oral cavity which may help elucidate the mechanisms by which 
mucosal ulceration occurs in BD. It was hypothesized that BD patients have insufficient levels of 
salivary SLPI and α1AT enabling excessive extracellular NE to damage the oral epithelial mucosa 
leading to cellular instability and recurrent ulcerations. The information deduced from this 
research may help improve targeted drug therapy to decrease recurrent episodes, increase the 
healing rate, and ultimately prevent ulceration.
MATERIALS AND METHODS
Patients and saliva sample collection
This study was approved by the local research ethics service of the City and East London 
(P/03/122). All subjects gave written consent and all samples were collected between 01/2009–
12/2012. STROBE cohort guidelines were followed. BD patients fulfilled the International Study 
Group Criteria (37). Although BD is a multisystem disorder, with a broad range of clinical 
manifestations, we focused on the oral environment and therefore in the manuscript refer to an 
active oral episode (BDa) as the presence of at least one oral ulcer at the time of sampling 
regardless of size, duration, or other clinical symptoms. BD and RAS ulcers can resolve and 
reoccur intermittently. If no oral ulcer was present at the time of sample collection, regardless of 
other systemic symptoms, the individual was deemed orally quiet, or BDq. A separate 
questionnaire for BD patients’ systemic symptoms was recorded on the day of their clinic. 
Evidence of disease activity at different sites such as their skin, genitals, or joints was recorded 
separately as quiet or active (Table S1). 
Saliva was collected from BD patients with active oral ulcers (BDa, n=93) and those without oral 
ulcers deemed BD quiet (BDq, n=103) at monthly-held Behçet’s daytime clinics at the Royal 
London Hospital. RAS subjects with active oral ulcers (RASa, n=19), RAS without ulcers (RASq, 
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ml of water for 10 seconds and expelled. Passive drooling of 1-5 ml of unstimulated saliva was 
collected into a sterile container, transferred to the laboratory on ice, and centrifuged at 3500g for 
15 min at 4°C. Supernatants were aliquoted and stored at -80°C until further analysis.
Salivary levels of SLPI, NE and α1AT
Enzyme linked immunosorbent assays (ELISA) were used to measure human SLPI (Quantikine®, 
R&D Systems, UK), NE (HK319, HyCult Biotech, The Netherlands) and α1AT (Genway Biotech, 
Inc, USA) in saliva following the manufacturers’ protocols. Table 1 summarizes the number of 
BD, RAS and HC saliva samples tested per assay. Saliva was diluted 1:200 in PBS and run in 
duplicate alongside standards. Initial validation experiments were carried out for each ELISA. 
This involved adding recombinant or purified target protein to ELISA wells alone or in the 
presence of BD saliva in order to assess the accuracy of the assays. Each ELISA successfully 
recovered the spiked amount at a 1:200 saliva dilution (acceptable recovery being between 80 – 
120%).
Elastase activity in saliva samples 
Total protease activity as well as NE-specific enzymatic activity in saliva was measured using the 
EnzChek® Elastase Assay Kit (Molecular Probes/Life Technologies, UK) as per the 
manufacturer’s instructions. The following patients’ saliva samples were tested: BDa n=7, BDq 
n=6, RASa n=4, RASq n=5, and HC n=8. First, BDa and RASa saliva samples were diluted 1:20 
using the 1X reaction buffer and those from BDq, RASq, and HC’s were diluted to 1:10. An 
aliquot of 100 µl of these diluted samples was added in duplicate to a 96-well plate containing 50 
µl of 800 µM NE inhibitor (N-Methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone) or 50 µl 
of 1X reaction buffer for the non-inhibited reaction. Next, 50 µl of 100 µg/ml of the DQTM Elastin 
conjugated with BODIPY® FL dye was added to each well to bring the final volume to 200 µl. 
Porcine elastase was provided as the protease activity positive control. Its reaction consisted of the 
same volume of DQTM Elastin with and without inhibitor. A negative control with only reaction 
buffer and DQTM Elastin was also included. With an excitation wavelength of 480 nm, emitted 
fluorescence at a wavelength of 520 nm was detected on an OPTIMA FLUOStar 
spectrophotometer (BMG Labtech, Germany) and recorded every 5 min for a total of 95 min at 
37oC. An increase in fluorescence during 95 minutes indicated high elastase activity in the saliva. 
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and total elastase activity (i.e. with and without inhibitor) was calculated in order to determine the 
NE-specific activity in each saliva sample.
Oral buccal swab sample collection 
A swab of oral buccal epithelial cells was collected from all participants in order to determine the 
extent of the local expression of SLPI mRNA other than from the saliva glands’ acini. Therefore, 
after saliva was collected, oral buccal swabs (OBS) were collected from HC, RAS, and BD 
patients by brushing the inside of the cheek sweeping up and down 10 times using a nylon 
cytology brush (Deltalab, Spain). If sloughed from an ulcerated site, the sample was denoted as 
“U” and if from a non-ulcerated site “NU”. Gentle pressure was used for obtaining swabs from 
ulcerated sites in order to minimize discomfort to patients. The brush was then vigorously washed 
in 400μl of RLT Buffer (Qiagen, UK). The samples were frozen on dry ice and transferred to -
80oC. 
Extraction, purification, and reverse transcription of RNA 
OBS were defrosted on ice and RNA extracted using the RNeasy Mini Kit (Qiagen, UK) as 
described by the supplier’s protocol followed by DNase enzyme digestion using TURBO™ DNA-
free kit (Ambion, UK). RNA quantity and quality were assessed using Nanodrop™ 1000 (Thermo 
Scientific, UK). A ratio of 1.7-2.0 indicated good quality RNA. Reverse transcription (RT) was 
performed on ≤ 2 µg per 20 µl reactions using the High Capacity cDNA Reverse Transcription Kit 
with RNase Inhibitor (Applied Biosystems, UK) as per the manufacturer’s instructions. Each 0.2 
ml reaction tube was placed into a Veriti Thermocycler (Thermo Scientific, UK) with the 
following incubation times and temperatures: 25oC for 10 min, 37oC for 120 min, and 85oC for 5 
min to deactivate the RT enzyme, and cooled to 4oC. The new complimentary (c)DNA was 
aliquoted and kept at -20oC.      
OBS reference gene panel
The Real-Time ready Human Reference Gene 384-well Panel (Roche, Germany) was used to test 
a panel of 19 potential reference genes in a total of 48 OBS from BD, RAS, and HC subjects. The 
manufacturer’s protocol was followed. For our plate set up, each cDNA sample was first diluted 
1:10 in RNase-free water to a final volume of 125 µl. To this, 125 µl of 2X LightCycler® 480 
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each well across an individual row (columns 1 – 23), i.e. each row consisted of one patient sample. 
A total of 16 patient RNA samples were applied to one plate. Column 23 and 24 (the RT-negative 
controls) each had 1 µl of the previously set aside non-transcribed OBS RNA sample, 4 µl of 
water, and 5 µl of the 2X LightCycler® 480 Probes Master reaction mix. Plates were sealed, 
centrifuged briefly, and run on the LightCycler® 480 System I instrument (Roche) by uploading 
the company provided macros program. 
 
SLPI and PPIA qPCR optimization 
All primers were designed based on human mRNA database sequences taking into account any 
multiple transcript variations. SLPI (accession NM003064.2) primers were designed by the 
Universal Probe Library program (Roche Applied Science, UK): SLPI F-primer: 
5’CTGTGGAAGGCTCTGGAAAG and SLPI R-primer 5’GGCACTGGGCAGATTTCTTA. 
Primer design for one of the most stable reference genes, peptidylprolyl isomerase A (PPIA, 
accession NM021130), was selected from RTPrimerDB: (F-primer 
5’TCATCTGCACTGCCAAGACTG, R-primer 5’CATGCCTTCTTTCACTTTGCC). Primers 
were manufactured by Sigma-Aldrich, UK.  
During quantitative (q)PCR assay optimization, primers underwent an initial reaction with 2X 
Sybr Green I Mastermix (Roche, UK) and at least 2 different cDNA OBS samples to ensure 
amplification of one product. In order to assess this, the melt temperature (Tm) of the amplicon 
was completed and water (negative) controls were run every time and monitored for any 
amplification. Single amplicon product sizes, 66 bp for SLPI and 71 bp for PPIA, were confirmed 
by DNA electrophoresis on a 1% agarose gel. Purified cDNA was subsequently used for 
standards. Since a pre-mixed 2X Sybr Green I Mastermix  was used for all reactions, dNTPs, Taq 
polymerase, and MgCl2 concentrations were all pre-determined by the manufacturer and therefore 
special consideration was spent on forward and reverse primer concentration as well as annealing 
temperature and time in order to optimize the individual assays.
The final qPCR assays for each target consisted of 400nM forward and reverse primers with 2X 
Sybr Green I Mastermix (Roche, UK) and 5 µl of cDNA in a final 12.5 µl reaction. Both assays 
were optimized to run at the same temperature cycles which included initial activation of Taq 
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for 10 sec on a LightCycler® 480 System I instrument (Roche, UK). A total of 86 OBS samples 
were analyzed for SLPI/PPIA mRNA (HC n=16; BDq n=27, BDa, NU n=20; BDa, U n=6; RASq 
n=11; RASa, NU n=4; RASa, U n=2).
Statistical analysis
IBM SPSS v23 was used to analyze ELISA and enzyme kinetics data using the non-parametric 
Mann-Whitney U test. Significance was based on 2-tailed, 95% confidence intervals (CI) where 
*p<0.05, **p<0.01, ***p≤0.001. Spearman’s rho with 2-tailed significance was used for 
correlation analysis. QBasePlus software V2.1 (Biogazelle, Belgium) was used for normalization 
of qPCR data followed by analysis using an unpaired t-test with Welch’s correction on GraphPad 
v.7.03. 
RESULTS
Salivary SLPI, NE and α1AT levels
BD and RAS patients with ulcers had significantly higher NE levels compared to those without 
ulcers. Figure 1A shows that BDa saliva (1794 ng/ml, median) and RASa saliva (3080.7 ng/ml) 
were significantly higher than all other groups without ulcers: BDq (1111.7 ng/ml, p<0.05), RASq 
(1043.4 ng/ml, p<0.05) and HC (998.9 ng/ml, p<0.01). The median NE level in the BDq group 
was higher than HC and RASq but not significantly so. 
However, SLPI was significantly reduced in BDq patient’s saliva (198.7 ng/ml, p<0.05) compared 
to HC and RAS and had the lowest median salivary SLPI levels amongst all groups (Figure 1B). 
BDa and RASa had similar levels of SLPI at 320.6 and 383 ng/ml, respectively, however only 
BDa saliva was significantly lower than RASq (p<0.01). SLPI levels were highest in HCs (487.3 
ng/ml) and RASq (860.1 ng/ml) patients. Spearman’s rho correlation analysis of n=37 BDq 
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(r = -0.195, p=0.25) compared to HC (r = -0.419, p=0.02) and BDa (r = -0.299, p=0.09) (see 
Suppl. Figure S1.)
Salivary α1AT levels were  significantly higher in BDq (8395.3 ng/ml) compared to HC (4995 
ng/ml, p<0.05) (Figure 1C). BDa α1AT (14,326.1 ng/ml) was nearly double the quantity of BDq 
and significantly higher than HC (p<0.001) but not BDq. RASa and RASq had higher α1AT levels 
than HC, but neither was significant. 
Although the focus was on investigating NE, SLPI, and α1AT levels in saliva, BD patients were 
also clinically assessed for other systemic symptoms (Table S1). BDq patients whose saliva was 
tested for NE, SLPI, and α1AT also commonly had painful joints (19, 21, 38%) and folliculitis 
(12, 14, 14%), respectively. The median saliva NE level for BDq patients experiencing joint pain 
and folliculitis were both 1843.6 ng/ml. There was no significant difference in the BDq salivary 
NE concentration when these two sites were recorded as clinically active (Figure S2. A). The 
median SLPI saliva concentration for BDq with joint pain was 147.3 ng/ml while those with 
folliculitis was 367.7 ng/ml. Again, there was no significant difference in the saliva levels when 
these two most common sites were active (Figure S2. B). However, when BDq had active joints 
(n=11), the α1AT in their saliva was significantly higher (p=0.02) (Figure S2. C). For BD patients 
with active oral ulcers the most frequent ailments were follicultis (34-46)%, followed closely by 
joint pain (33-44%), and genital ulcers (25-33%) (Table S1). The NE, SLPI, and α1AT saliva 
levels in BDa patients were not significantly higher when they were experiencing folliculitis or 
joint pain (Figure S2. D-F),
Salivary NE levels and patient medications
While no systemic medications were reported for HC or RAS groups, similar numbers of BDa and 
BDq patients were receiving immunomodulatory medications at the time of sample collection 
(Table S2). Saliva samples were chosen from this cohort based on active or quiet ulcer status. The 
medications were analysed as a secondary variable. 
Salivary NE levels were measured in both BDa and BDq patients taking colchicine (COLC) or 
azathioprine (AZA), both, or neither COLC or AZA (Figure 2). Although there was no significant 
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azathioprine tended to have increased NE (2309 ng/ml). However, the NE levels in BDa patients 
on both COLCand AZA were significantly lower (1131 ng/ml) compared to those taking only 
colchcine (1816 ng/ml, p=0.0008) or those on neither COLC or AZA (2141 ng/ml, p=0.02). This 
group of BDa patients on COLC and AZA had similar NE levels to healthy controls (999 ng/ml, 
Figure 2A) and although this group consisted of a small number of patients (n=7), they exhibited 
a narrow range of NE levels (490–1347 ng/ml).
Enzymatically active NE in saliva
Elastin-specific proteases were measured, and HC saliva had the lowest overall protease activity 
compared to all other study groups (Figure 3A) based on an equal amount of elastin substrate 
being added to each saliva sample. Within 95min of exposure to the substrate, the total protease 
and NE enzyme activity was significantly higher in both BDa and BDq patients compared to HC 
(p<0.05). When comparing each group’s NE activity relative to their total protease activity, there 
were no significant differences (Figure 3B). This was determined by dividing the median 
fluorescence of the NE-specific activity by the total protease activity fluorescence for each group 
and multiplying by 100. The NE in HC saliva comprised ~78% of the total protease activity. 
Similarly, RAS and BD saliva samples also showed that 79.6% and 82.8% of their total protease 
activity respectively was due to NE.
Stable reference genes in OBS
Duplicate SLPI Cq values were averaged and normalised (Calibrated Normalized Relative 
Quantity) using the qBasePlus (Biogazelle software, Belgium) against the Cq values for the PPIA 
reference gene. Out of 48 OBS, 13 samples were excluded from analysis due to a final Cq value > 
40. RASa, U samples were completed but not included in analysis due to the small sample size, 
only n=2. None of the RT-negative samples amplified and were therefore clear of any gDNA 
contamination. The four most stable reference genes validated for BD, RAS, and HC OBS were 
peptidylprolyl isomerase A (PPIA), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
phosphoglycerate kinase 1 (PGK1), and beta-actin (ACTB) (Figure S3). PPIA primers performed 
the most efficiently and due to the limited amount of material for multiple assays, this reference 
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SLPI mRNA expression
SLPI mRNA was significantly increased in BDa, NU (p≤0.01) and BDa, U (p≤0.05) when 
compared to HC (Figure 4). Also, SLPI mRNA was significantly upregulated in BDq (p≤0.001) 
compared to HC and RASq (p≤0.05). Unfortunately, the only two RASa, U samples available 
showed a wide variable range and were therefore excluded from final analysis. 
DISCUSSION
Increased circulating neutrophils and their degranulated enzyme, NE, have previously been 
implicated in the systemic chronic inflammatory response in BD (14, 15). The recurrent oral ulcers 
that accompany BD may also result from unregulated NE-stimulated inflammation. As observed 
in a previous study, it was thought that protective salivary SLPI would increase during oral 
ulceration since it has been shown to aid wound healing (38). We report here for the first time that 
during quiet oral episodes in which BD mucosa is not ulcerated, individuals with BD have active 
proteolytic NE in their saliva in quantities similar to HCs and RASq subjects; however, levels of 
SLPI in BDq are significantly lower. Taken together these results indicate that the presence of 
active NE and reduced SLPI may be contributing factors to initiation of BD oral ulceration 
(Figure 5). Another endogenous inhibitor, α1AT, despite its abundance in saliva, does not appear 
to affect NE activity. The results suggest that there is an association between high levels of 
proteolytic enzymes and oral mucosal instability leading to oral ulceration. Furthermore, our data 
shows that BDa patients medicated with both AZA and COLC have reduced salivary NE.
The Inverse Relationship of NE and SLPI 
All individuals had quantifiable NE and SLPI in their saliva. Our data shows a ratio of 2:1 
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antibody detection of each protein. While NE increased during oral ulceration in RAS and BD 
patients, BDq patients had only slightly higher NE levels than HC’s, but showed a significant 
reduction of SLPI (the lowest of all groups) giving a concentration ratio of 5:1 NE:SLPI – 
precisely the same NE:SLPI ratio as BDa levels. This suggests that SLPI is depleted in BDq 
patients despite being orally asymptomatic. A similar inverse NE/SLPI dynamic has been 
previously reported in active periodontitis saliva (39) and reduced SLPI has been associated with 
periodontal disease progression (40).
SLPI has two structural domains allowing the binding of two different targets (29). We therefore 
postulated that since SLPI derived from whole saliva could simultaneously bind to both NE and a 
different second target (such as a microbe) this could block SLPI detection by ELISA antibody. To 
further validate and scrutinize the reduction of SLPI in our BDq cohort, we conducted a spike-
recovery ELISA experiment. After adding known concentrations of recombinant (r)SLPI into BDq 
saliva in which SLPI had previously been measured, the detection recovery of rSLPI was between 
89 – 99%. This provided us with evidence that the ELISA detection was accurate despite the 
possibility of SLPI to be masked while exposed to multiple targets in saliva. 
Other reasons for the depletion of SLPI in saliva may involve cysteine proteases such as 
cathepsins or chymase, a serine protease from mast cells, which can cleave and inactivate SLPI 
(39). NE has also been shown to directly degrade SLPI which could explain the inverse 
concentration levels (41). Another reason for the lower SLPI concentration could be due to its 
direct attachment to oral microbes. There is strong evidence that SLPI has broad spectrum 
antimicrobial activity (29). In a study by Seoudi, et al, the oral bacterial profile of BD and RAS 
patients with and without ulcers and HCs revealed that the different subject groups had different 
bacterial species colonization (42). Microbial flora has been previously implicated in BD 
pathogenesis (43) which may further explain their decreased levels of SLPI.
Increased SLPI mRNA but decreased SLPI protein is characteristic during BDq 
Reduced SLPI levels could also indicate that sufficient levels of SLPI were not available in the 
first place. This would be especially detrimental in an inflammatory condition such as BD in 
which regulation of pro-inflammatory factors is vital to reduce symptoms. This prompted us to 
investigate local SLPI mRNA expression. Both saliva gland acini and epithelial cells contribute to 
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mRNA expression in the oral epithelium using buccal swabs. The vast majority of studies 
investigating oral buccal epithelial cell RNA involves oral squamous cell carcinoma and many do 
not mention validation of their reference genes. To date, this is the first study to report stable RNA 
reference genes in OBS from HC as well as BD and RAS patients with and without oral ulcers and 
is explored in depth in the Supplement Part II.
   
The expectation was that SLPI mRNA would be reduced reflecting the low salivary levels. 
Surprisingly, the results indicated that SLPI mRNA was significantly upregulated in BDq patients’ 
buccal epithelial cells. A similar paradox was reported in an in vitro experiment by Sallenave, et 
al, in which NE was used to stimulate A549 epithelial cells. After 24 hrs, SLPI protein levels were 
decreased by 94% while SLPI mRNA was upregulated (44).The rate of translation (mRNA to 
protein), production, and cellular exocytosis of SLPI is unknown for buccal epithelial cells, 
however ex vivo human upper respiratory tract submucosal cells have shown a delay of SLPI 
exocytosis after NE exposure (45). We speculate that once SLPI is available in the extracellular 
space in the presence of high levels of NE, it is rapidly utilized.
In BDa patients, the upregulation of SLPI mRNA could be directly stimulated by high levels of 
salivary NE. However, what is decisively characteristic is that BDq patients with no oral 
ulceration have the highest SLPI mRNA expression, lowest salivary SLPI, and NE levels on par 
with HC and RASq. This suggests that BDq patients are likely more sensitive to NE stimulation in 
comparison to HC or RAS patients. Also, the SLPI mRNA data provides compelling evidence of a 
differentiation between the oral mucosal environment of BDq and RASq patients. 
A small portion of the BDq patients in this study presented with other systemic clinical 
manifestations such as joint pain, skin lesions, and genital ulcers at the time of their saliva 
donation demonstrating their underlying systemic inflammatory activity. Although the numbers 
were small, it was found that only salivary α1AT levels were  significantly increased in BDq 
patients with active joint pain (p=0.02). This could be due to increased α1AT production by the 
liver and vascular dissemination. None of the BDa patients showed any significant difference in 
their NE, SLPI, or α1AT saliva levels when assessing their most common systemic symptoms. 
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systemic activity. Therefore, importantly, when assessing SLPI as a biomarker in BDq patients, 
other systemic symptoms should not greatly influence the oral concentration.
Even though our data did not show significantly higher NE saliva levels during other active 
systemic symptoms, increased circulating peripheral blood neutrophils are likely to influence 
tissue and oral infiltration. A study by Deger, et al, showed elevated levels of NE in plasma from 
22 BD orally quiet patients compared to HC (14). Further studies are required that measure NE, 
SLPI and α1AT levels in matched serum and saliva of BD patients to explore if there is a more 
robust correlation with clinical activity in the mouth, eyes, skin, joints and CNS.
Lakschevitz, et al, have reported that oral and peripheral blood neutrophils from HC’s behave 
differently. Based on microarray data, they found that HC salivary neutrophil RNA changed their 
transcriptome when they migrated from the blood to the oral environment. This alteration was 
especially evident during increased oral infection or inflammation (46, 47) It has also been 
suggested that neutrophils are already primed by chemotactic factors such as IL-8 or TNF-α by the 
time they reach the oral cavity (48). There is, therefore a need to keep in mind that oral neutrophils 
are exposed to different microbial, antigen and toxin conditions in saliva when compared to blood, 
which can influence the release of potent anti-microbial proteases such as NE into the saliva and 
oral cavity (49).
Importantly, during quiet oral episodes, increased NE degranulation in saliva would likely rely on 
local anti-protease activity such as SLPI to curtail epithelial damage. Our data suggest that SLPI’s 
depletion in BDq saliva may be a key factor in the manifestation of oral ulcers. It may benefit BD 
patients to use a local, topical NE-inhibitor such as a compound containing rSLPI to help control 
recurring oral ulceration (50). 
Salivary Proteases and NE Activity
NE was confirmed to be enzymatically active in saliva and responsible for the majority of protease 
activity. It was anticipated that patients with ulcers would have increased NE activity since the 
ulcerated wound would have initiated neutrophil recruitment to the site. However, BDq and RASq 
also had higher NE activity compared to HCs. Individuals with BD have been described as having 
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oral NE is also present. Under-regulated, enzymatically active NE in BD saliva is likely to 
contribute to recurrent mucosal damage and ulceration characteristic of BD.
α1AT is Not the Main NE Inhibitor in Saliva
NE and α1AT showed a direct relationship – if NE increased, α1AT also increased. In HCs, α1AT 
was five times the NE concentration and approximately ten times that of SLPI. SLPI and α1AT are 
competitors in that they both inhibit NE. Both also reside inside neutrophils (34) presumably 
protecting neutrophils from unintentional self-induced proteolytic damage. The majority of α1AT 
is produced in liver cells. Approximately 1-2 g/L is transferred to plasma and up to 10% diffuses 
into biological fluids such as saliva (51). As a serpin, α1AT is thought to irreversibly bind and 
inactivate NE (52), yet in our enzyme assay, salivary NE was proteolytically active. This leads us 
to deduce that despite the abundance of α1AT in saliva, it is not the main inhibitor of NE in the 
oral cavity. Also, various proteases can inactivate α1AT such as collagenase (53), therefore, it is 
also possible that α1AT’s inhibitory site, which is susceptible to oxidation, is inactivated by 
reactive oxygen species generated by phagocytic cells and bacteria in saliva (54).
Colchicine-Azathioprine May Lower NE during BD Ulceration 
The combination of COLC and AZA medications is associated with decreased NE in BDa saliva. 
COLC is one of the recommended medications for treating mucocutaneous lesions by reducing the 
migration of neutrophils (18) and has been shown to modulate oxidative stress in BD neutrophils 
by regulating Ca2+ release (55). In combination with AZA, we sought to determine whether this 
combination of systemic medication influences oral NE levels. We found that BDa patients taking 
both medications had significantly lower NE which was surprising during ulceration. Despite the 
small sample size, the narrow range of their NE measurements indicates low variability. AZA is 
an immunosuppressive drug which lowers the proliferation of lymphocytes (56). Colchicine 
accumulates in WBC’s (namely neutrophils) disrupting various inflammatory activation, 
degranulation, and migration processes (57). Coupled together, the drugs’ synergistic effects of 
reducing WBC’s and proinflammatory activities, thus decreasing NE degranulation, may help to 
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There are some limitations to this study. First, RAS subjects were sought as a non-systemic 
disease controls from general oral medicine clinics and from local adverts, but recruitment was  
lower than expected compared to our BD cohort which was recruited from dedicated specialist BD 
clinics. Individuals with RAS are thought to endure a unique immune dysregulation which, for 
unknown reasons, manifests solely in the oral cavity (58). Furthermore, Ueta, et al, have suggested 
that individuals with RAS may harbour an immune cell dysfunction based on the evidence that 
their neutrophils had suppressed superoxide production compared to HCs (59). Overall, it was 
rationalised that the RAS group, although having small patient numbers, would still add further 
important insights into oral ulceration mechanisms for which there is very little known.
 Another limitation presented itself when directly swabbing mucosal ulcers too gently with 
cytology swabs as this did not generate enough RNA for all analyses. In future collections, a softer 
swab that would be both gentle to patient’s ulcerated mucosa and compatible with PCR assays 
would be used. Another consideration for future research would be to collect data on the subject’s 
smoking status, race, duration of treatment, and alterations in treatment regimens. Also, relatively 
large volumes of saliva were necessary to  run NE, SLPI, α1AT and enzyme activity assays in 
duplicate. Therefore, it was not possible to run all the analyses on the same set of saliva samples 
which resulted in unequally sized groups for the different assays. Although BD is a rare disorder, 
this research study benefited from a substantial number of participants thanks to their attendance 
and recruitment at the Royal London Hospital’s specialized clinic. 
In conclusion, this study was able to describe the depletion of SLPI in BD saliva during orally 
asymptomatic episodes and highlights its potential in balancing the damage caused by 
enzymatically active, excessive NE. As biomarkers, the collective measurements of NE and SLPI 
in saliva alongside oral epithelial SLPI mRNA could differentiate between RASq and BDq to 
assist clinical evaluation. Early intervention could be key to controlling the progression of 
inflammation associated with BD.. During oral ulceration, the current combined treatment with 
colchicine and azathioprine seems to lower NE in saliva which could help control inflammation. 
As a local, topical treatment, recombinant SLPI is commercially available and has been trialed in 
other inflammatory disorders (50, 60, 61). This study also found that α1AT, the most well-known 
NE-inhibitor in the vasculature, did not seem to translate its anti-protease activity in saliva – again 
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Figure Legends
Figure 1. Saliva Protein Levels Amongst Patient Groups. Tukey boxplots show A. NE B. SLPI, 
and C. α1AT levels in HC (healthy control), RAS (recurrent aphthous stomatitis), and BD 
(Behçet’s disease) patients. q, indicates quiet episode/no ulcers. a, refers specifically to at least 
one active mouth ulcer regardless of other systemic symptoms. Each saliva sample was measured 
in duplicate. Mann-Whitney U test was used to assess differences between two groups at a time. 
Significance based on 2-tailed, 95% CI. *p<0.05, **p<0.01, ***p<0.001. 
Figure 2. Saliva NE levels of BD patients taking systemic colchicine and/or azathioprine 
during quiet or active oral ulceration. The Tukey box plots show ELISA NE levels in the 
following groups: BDq patients with no oral ulceration at the time of sampling and BDa patients 
who had oral ulcer(s). Patients were identified as taking colchicine (COLC) or azathioprine 
(AZA), both, or neither AZA or COLC. “COLC only” refers to the exclusion of AZA and vice 
versa, however, does not exclude other medications the patient may have been taking. Mann-
Whitney U test, significance based on 2-tailed, 95% CI. Exact p values are indicated. NS, no 
significance.
Figure 3. Although the quantity of neutrophil elastase differs among patient groups, it makes 
up the majority of elastin-targeting proteases in saliva. The total protease and NE-specific 
activity were measured in saliva samples based on the breakdown and release of fluorescent-
conjugated elastin. Saliva samples were tested in duplicate from each patient group: HC n=8, BDq 
(quiet, no ulcer) n=6, BDa (active oral ulcer) n=7, RASq n=5, RASa n=4. A. The black bars 
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bars represent the level of NE-specific activity for the same saliva samples. Error bars are 5% of 
the group median. Porcine elastase was used as a positive control. Mann Whitney U test, *p<0.05. 
Only significant differences are indicated. B. Percentage of NE activity relative to the total 
protease activity (group median values). Error bars indicate the interquartile region. The enzymatic 
ability of NE to digest elastin was similar in all groups regardless of ulceration.
Figure 4. Mean SLPI mRNA Expression in Oral Buccal Swabs amongst Different Patient 
Groups. SLPI Cq normalised using PPIA as the reference gene and compared among HC (healthy 
control), RAS (recurrent aphthous stomatitis), BD (Behçet’s disease). q, indicates quiet, no ulcers. 
a, refers to at least one active mouth ulcer regardless of other systemic symptoms. NU = swab 
taken from the buccal mucosa away from the oral ulcer. U = swab taken directly from the ulcer. 
Data analyzed using unpaired t-test with Welch’s correction (2-tailed, 95% CI). *p≤0.05, 
**p≤0.01, ***p≤0.001.
Figure 5. Proposed Working Model of Behҫet’s Disease Oral Environment: Summary of the 
Interaction of the Epithelium, Neutrophil Elastase, SLPI and α1AT. Individuals with BD have 
an increased presence of neutrophils in their vasculature which are recruited to the oral cavity due 
to hypersensitivity to ever-present microbes and proinflammatory cytokines (TNF-α, IL-8) 
produced by oral epithelial keratinocytes and immune cells. Fibroblasts and leukocytes further 
contribute IL-1β which induces additional IL-8 production – a neutrophil chemoattractant. 
Neutrophils continue to migrate through the epithelium towards the site of accumulating 
inflammatory signals. Neutrophils phagocytose foreign entities or degranulate releasing NE into 
the extracellular environment. Activated neutrophils also release IL-8 thus reinforcing a cycle of 
inflammation. Neutrophils may apoptose shortly after controlled degranulation, but may become 
necrotic or undergo NETosis which releases NE non-discriminately. Salivary glands and epithelial 
cells work to produce SLPI to counteract the excessive NE, but SLPI is steadily used up. Although 
serum-derived α1AT is carried to the oral cavity, there is no evidence that it can reduce NE 
activity. Neutrophils also have intracellular α1AT and SLPI reserves, but the extent of their 
external inhibitory contribution is not known. Excessive, prolonged exposure to NE can directly 
damage epithelial cells and the integrity of the mucosal lining by breaking down ECM resulting in 









Fluctuations of these inflammatory elements and reduced healing components may contribute to 
the recurrent ulcers seen in this disease. (Created using BioRender).
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 HC* 54 33 (29, 50) 33.3% 
 BDq 59 38 (31, 49) 30.5% 
 BDa 49 39 (29, 44) 36.7% 
 RASq 10 42 (24, 45) 40% 











 HC* 49 32 (29, 48) 34.7% 
 BDq 56 37 (31, 49) 33.9% 
 BDa 52 39 (28, 47) 36.5% 
 RASq 11 40 (27, 45) 36.4% 











 HC* 19 30 (27, 31) 36.8% 
 BDq 29 43 (35, 49) 34.5% 
 BDa 32 42 (29, 50) 31.3% 
 RASq 5 35 (24, 47) 37.5% 
 RASa 4 38 (27, 45) 25.0% 
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